Hejin Jia
No. 28 Fuxing Road
Beijing, 100853, China
Beijing, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma.
Journal: Blood advances
Published: September 23, 2021
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Journal: Journal of hematology & oncology
Published: May 20, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Journal: Journal of hematology & oncology
Published: January 06, 2020
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment.
Journal: Cellular & molecular immunology
Published: December 02, 2019
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
Journal: Journal of hematology & oncology
Published: February 27, 2019
Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 25, 2017
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 13, 2017
Anti-CD19 chimeric antigen receptor T cells (CART-19) for hemotological malignancies therapy
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 26, 2016
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Journal: Science China. Life sciences
Published: January 16, 2016
Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy.
Journal: Experimental and therapeutic medicine
Published: January 10, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026